$JANX News

Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $26

Wedbush Maintains Outperform on Janux Therapeutics, Lowers Price Target to $36

Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $58

Jones Trading Maintains Buy on Janux Therapeutics, Lowers Price Target to $28

Janux Therapeutics Halts Early Stage Cancer Program In 'Prudent' Move

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

Janux Therapeutics Discontinues JANX008 Cancer Program To Prioritize Higher-Potential Pipeline Opportunities

Barclays Downgrades Janux Therapeutics to Underweight, Lowers Price Target to $14

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

Janux Therapeutics Doses First Participant In Phase 1 Clinical Study Of JANX014 To Treat Metastatic Castration-Resistant Prostate Cancer

Sector Update: Health Care Stocks Decline Late Afternoon

Sector Update: Health Care Stocks Lower in Afternoon Trading

UBS Downgrades Janux Therapeutics to Neutral, Lowers Price Target to $15

Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial

Cantor Fitzgerald Maintains Overweight on Janux Therapeutics, Lowers Price Target to $100

Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $68

Janux Therapeutics Q4 EPS $(0.51) Beats $(0.64) Estimate

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

Vir Biotechnology: The Low-Down On The Readouts Ahead

Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion